Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet

Document -

Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet

go to media item
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
File format:
.pdf

Contacts

General Press Enquiries

Press contact 01628 925200

Joanna Jones

Press contact Head of Brand Communications and Patient Relations 07795 590 344

Cheryl Pitcher

Press contact Senior Corporate Communications Manager Internal and Corporate Communications 07500 786 466

Natalie Bennett

Press contact Senior Communications and Patient Relations Manager Immunology - Gastroenterology & Rheumatology 07818 428 074

Sarah Beck

Press contact Senior Brand Communications and Patient Relations Manager, Dermatology Dermatology 07818 428 111

Related content

Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet


SELECT-MONOTHERAPY evaluates the safety and efficacy of upadacitinib monotherapy in adult patients with moderately to severely active rheumatoid arthritis and inadequate response to a stable dose of methotrexate1 Upadacitinib (15 mg and 30 mg), once daily, achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity (defined as DAS28[CRP]≤

Enter your email address to follow AbbVie UK

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow AbbVie UK.

Okay